Exceptional response to neoadjuvant capecitabine and temozolomide in TSC2-mutant pancreatic neuroendocrine tumor
Robin Park, Deyali Chatterjee, Manik Amin and 1 more
Current Problems in Cancer: Case Reports · 2020
doi:10.1016/j.cpccr.2020.100037 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Tuberous Sclerosis 1/2 (TSC1/2) functions as a negative regulator of the mammalian target of rapamycin (mTOR) pathway, one of the key oncogenic pathways described in neuroendocrine neoplasm (NEN) carcinogenesis. While loss-of-function mutations in TSC1/2 lead to disinhibition of mTOR and uncontrolled cellular growth and proliferation, they concomitantly result in p53 sensitivity which manifests functionally as sensitivity to DNA damage. Here we report a case of a 57-year old male patient with a well-differentiated pancreatic NEN (PanNEN) who underwent neoadjuvant chemotherapy with capecitabine and temozolomide and achieved a near-complete pathologic response. The unusual response prompted further tumor characterization with next-generation sequencing which demonstrated a previously uncharacterized mutation in TSC2. We hypothesize that the TSC2 mutation may have contributed towards the exceptional response to the DNA damaging alkylating agent-based chemotherapy regimen. Furthermore, this case warrants the evaluation of alkylating agent-based chemotherapy regimens in NENs harboring mutations in mTOR pathway negative regulators such as TSC1/2.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.